AGWCA
TGTX icon

Annis Gardner Whiting Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$100 – 1155
2026
Q1 		$100 Buy
+3
New +$89 ﹤0.01% 1288
2025
Q4 		– Sell
-42
Closed -$1.52K – 1343
2025
Q3 		$1.52K Sell
42
-3
-7% -$99 ﹤0.01% 922
2025
Q2 		$1.62K Buy
+45
New +$1.68K ﹤0.01% 995

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's TGTX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 3 shares — an estimated $100 sold.

Annis Gardner Whiting Capital Advisors first reported a position in TGTX in Q2 2025 and held it in 3 quarters. The position peaked at $1.62K in Q2 2025. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 3 TG Therapeutics shares in Q2 2026, an estimated $100.
  • Annis Gardner Whiting Capital Advisors first reported a position in TG Therapeutics in Q2 2025 and held it in 3 quarters.
  • Annis Gardner Whiting Capital Advisors's TG Therapeutics position peaked at $1.62K in Q2 2025.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.